In two phase III randomized placebo-controlled studies in MM41 and NHL patients,42 the combination of G-CSF plus plerixafor was found to be safe and superior in terms of mobilization efficacy as compared to G-CSF plus placebo. Here, CSF3 is linked to non-Hodgkin lymphoma.